25 results on '"Ginsberg, Henry N"'
Search Results
2. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
- Author
-
Glesby MJ, Albu J, Chiu YL, Ham K, Engelson E, He Q, Muthukrishnan V, Ginsberg HN, Donovan D, Ernst J, Lesser M, and Kotler DP
- Subjects
- Abdominal Fat drug effects, Blood Glucose metabolism, Body Composition drug effects, Double-Blind Method, Female, Glucose Tolerance Test, Homeostasis, Human Growth Hormone adverse effects, Humans, Insulin-Like Growth Factor I metabolism, Lipid Metabolism drug effects, Male, Middle Aged, Placebos, Recombinant Proteins pharmacology, Rosiglitazone, Thiazolidinediones adverse effects, Thiazolidinediones pharmacology, Abdominal Fat metabolism, HIV Infections drug therapy, Human Growth Hormone therapeutic use, Insulin Resistance, Recombinant Proteins therapeutic use, Thiazolidinediones therapeutic use
- Abstract
Background: Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected patients but can worsen glucose homeostasis and lipoatrophy. We aimed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects of rhGH on insulin sensitivity (SI) and subcutaneous adipose tissue (SAT) volume., Methodology/principal Findings: Randomized, double-blind, placebo-controlled, multicenter trial using a 2×2 factorial design in which HIV-infected subjects with abdominal obesity and insulin resistance were randomized to rhGH 3 mg daily, rosiglitazone 4 mg twice daily, combination rhGH + rosiglitazone, or double placebo (control) for 12 weeks. The primary endpoint was change in SI by frequently sampled intravenous glucose tolerance test from entry to week 12. Body composition was assessed by whole body magnetic resonance imaging (MRI) and dual Xray absorptiometry (DEXA). Seventy-seven subjects were randomized of whom 72 initiated study drugs. Change in SI from entry to week 12 differed across the 4 arms by 1-way ANCOVA (P = 0.02); by pair-wise comparisons, only rhGH (decreasing SI; P = 0.03) differed significantly from control. Changes from entry to week 12 in fasting glucose and glucose area under the curve on 2-hour oral glucose tolerance test differed across arms (1-way ANCOVA P = 0.004), increasing in the rhGH arm relative to control. VAT decreased significantly in the rhGH arms (-17.5% in rhGH/rosiglitazone and -22.7% in rhGH) but not in the rosiglitazone alone (-2.5%) or control arms (-1.9%). SAT did not change significantly in any arm. DEXA results were consistent with the MRI data. There was no significant rhGH x rosiglitazone interaction for any body composition parameter., Conclusions/significance: The addition of rosiglitazone abrogated the adverse effects of rhGH on insulin sensitivity and glucose tolerance while not significantly modifying the lowering effect of rhGH on VAT., Trial Registration: Clinicaltrials.gov NCT00130286.
- Published
- 2013
- Full Text
- View/download PDF
3. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status.
- Author
-
Kitade H, Sawamoto K, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, Takamura T, Yamamoto H, Miyamoto K, Ginsberg HN, Mukaida N, Kaneko S, and Ota T
- Subjects
- Adipose Tissue physiopathology, Animals, Diet, High-Fat, Fatty Liver metabolism, Glucose Intolerance metabolism, Inflammation physiopathology, Macrophages metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Obese, Receptors, CCR5 genetics, Up-Regulation, Adipose Tissue metabolism, Inflammation metabolism, Insulin Resistance physiology, Macrophage Activation physiology, Obesity metabolism, Receptors, CCR5 physiology
- Abstract
C-C motif chemokine receptor (CCR)2 and its ligand, monocyte chemoattractant protein (MCP)-1, are pivotal for adipose tissue macrophage (ATM) recruitment and the development of insulin resistance. However, other chemokine systems also may play a role in these processes. In this study, we investigated the role of CCR5 in obesity-induced adipose tissue inflammation and insulin resistance. We analyzed expression levels of CCR5 and its ligands in white adipose tissue (WAT) of genetically (ob/ob) and high-fat (HF) diet-induced obese (DIO) mice. Furthermore, we examined the metabolic phenotype of Ccr5(-/-) mice. CCR5 and its ligands were markedly upregulated in WAT of DIO and ob/ob mice. Fluorescence-activated cell sorter analysis also revealed that DIO mice had a robust increase in CCR5(+) cells within ATMs compared with chow-fed mice. Furthermore, Ccr5(-/-) mice were protected from insulin resistance, glucose intolerance, and hepatic steatosis induced by HF feeding. The effects of loss of CCR5 were related to both reduction of total ATM content and an M2-dominant shift in ATM polarization. It is noteworthy that transplantation of Ccr5(-/-) bone marrow was sufficient to protect against impaired glucose tolerance. CCR5 plays a critical role in ATM recruitment and polarization and subsequent development of insulin resistance.
- Published
- 2012
- Full Text
- View/download PDF
4. Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.
- Author
-
Li G, Hernandez-Ono A, Crooke RM, Graham MJ, and Ginsberg HN
- Subjects
- 11-beta-Hydroxysteroid Dehydrogenase Type 1 antagonists & inhibitors, 11-beta-Hydroxysteroid Dehydrogenase Type 1 metabolism, Animals, Body Composition genetics, Body Composition physiology, Eating genetics, Energy Metabolism genetics, Glucose Tolerance Test, Insulin metabolism, Insulin Resistance genetics, Male, Mice, Mice, Inbred C57BL, Signal Transduction genetics, Signal Transduction physiology, 11-beta-Hydroxysteroid Dehydrogenase Type 1 genetics, Adipose Tissue metabolism, Eating physiology, Energy Metabolism physiology, Insulin Resistance physiology
- Abstract
We recently reported that inhibition of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) by antisense oligonucleotide (ASO) improved hepatic lipid metabolism independent of food intake. In that study, 11β-HSD1 ASO-treated mice lost weight compared with food-matched control ASO-treated mice, suggesting treatment-mediated increased energy expenditure. We have now examined the effects of 11β-HSD1 ASO treatment on adipose tissue metabolism, insulin sensitivity, and whole-body energy expenditure. We used an ASO to knock down 11β-HSD1 in C57BL/6J mice consuming a Western-type diet (WTD). The 11β-HSD1 ASO-treated mice consumed less food, so food-matched control ASO-treated mice were also evaluated. We characterized body composition, gene expression of individual adipose depots, and measures of energy metabolism. We also investigated glucose/insulin tolerance as well as acute insulin signaling in several tissues. Knockdown of 11β-HSD1 protected against WTD-induced obesity by reducing epididymal, mesenteric, and subcutaneous white adipose tissue while activating thermogenesis in brown adipose tissue. The latter was confirmed by demonstrating increased energy expenditure in 11β-HSD1 ASO-treated mice. The 11β-HSD1 ASO treatment also protected against WTD-induced glucose intolerance and insulin resistance; this protection was associated with smaller cells and fewer macrophages in epididymal white adipose tissue as well as enhanced in vivo insulin signaling. Our results indicate that ASO-mediated inhibition of 11β-HSD1 can protect against several WTD-induced metabolic abnormalities. These effects are, at least in part, mediated by increases in the oxidative capacity of brown adipose tissue., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
5. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.
- Author
-
Choi SH and Ginsberg HN
- Subjects
- Humans, Fatty Liver physiopathology, Insulin Resistance physiology, Lipoproteins, VLDL metabolism
- Abstract
Insulin resistance (IR) affects not only the regulation of carbohydrate metabolism but all aspects of lipid and lipoprotein metabolism. IR is associated with increased secretion of VLDL and increased plasma triglycerides, as well as with hepatic steatosis, despite the increased VLDL secretion. Here we link IR with increased VLDL secretion and hepatic steatosis at both the physiologic and molecular levels. Increased VLDL secretion, together with the downstream effects on high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) size, is proatherogenic. Hepatic steatosis is a risk factor for steatohepatitis and cirrhosis. Understanding the complex inter-relationships between IR and these abnormalities of liver lipid homeostasis will provide insights relevant to new therapies for these increasing clinical problems., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
6. Effects of a 1,3-diacylglycerol oil-enriched diet on postprandial lipemia in people with insulin resistance.
- Author
-
Reyes G, Yasunaga K, Rothenstein E, Karmally W, Ramakrishnan R, Holleran S, and Ginsberg HN
- Subjects
- Adolescent, Adult, Aged, Cross-Over Studies, Diet Therapy, Diglycerides pharmacology, Double-Blind Method, Female, Humans, Hyperlipidemias epidemiology, Hypertriglyceridemia diet therapy, Male, Middle Aged, Treatment Outcome, Diglycerides administration & dosage, Hyperlipidemias diet therapy, Insulin Resistance, Postprandial Period
- Abstract
Postprandial hypertriglyceridemia is common in individuals with insulin resistance, and diets enriched in 1,3-diacylglycerol (DAG) may reduce postprandial plasma triglycerides (PPTGs). We enrolled 25 insulin-resistant, nondiabetic individuals in a double-blind, randomized crossover trial to test the acute and chronic effects of a DAG-enriched diet on PPTG. Participants received either DAG or triacylglycerol (TAG) oil, in food products, for 5 weeks. Fasting lipids, and two separate postprandial tests, one with DAG oil and one with TAG oil, were performed at the end of each 5 week diet period. We found no acute or chronic effects of DAG oil on PPTG. Thus, neither the DAG oil PPTG (h/mg/dl) on a chronic TAG diet [area under the curve (AUC) = 503 +/- 439] nor the TAG oil PPTG on a chronic DAG diet (AUC = 517 +/- 638) was different from the TAG oil PPTG on a chronic TAG diet (AUC = 565 +/- 362). Five weeks of a DAG-enriched diet had no acute or chronic effects on PPTG in insulin-resistant individuals. We suggest further studies to evaluate the effects of DAG on individuals with low and high TG levels.
- Published
- 2008
- Full Text
- View/download PDF
7. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis.
- Author
-
Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, and Kahn CR
- Subjects
- Animals, Disease Susceptibility, Hypercholesterolemia etiology, Lipoproteins blood, Liver Diseases, Mice, Mice, Knockout, Receptor, Insulin deficiency, Atherosclerosis etiology, Dyslipidemias etiology, Insulin Resistance
- Abstract
Insulin resistance plays a central role in the development of the metabolic syndrome, but how it relates to cardiovascular disease remains controversial. Liver insulin receptor knockout (LIRKO) mice have pure hepatic insulin resistance. On a standard chow diet, LIRKO mice have a proatherogenic lipoprotein profile with reduced high-density lipoprotein (HDL) cholesterol and very low-density lipoprotein (VLDL) particles that are markedly enriched in cholesterol. This is due to increased secretion and decreased clearance of apolipoprotein B-containing lipoproteins, coupled with decreased triglyceride secretion secondary to increased expression of Pgc-1 beta (Ppargc-1b), which promotes VLDL secretion, but decreased expression of Srebp-1c (Srebf1), Srebp-2 (Srebf2), and their targets, the lipogenic enzymes and the LDL receptor. Within 12 weeks on an atherogenic diet, LIRKO mice show marked hypercholesterolemia, and 100% of LIRKO mice, but 0% of controls, develop severe atherosclerosis. Thus, insulin resistance at the level of the liver is sufficient to produce the dyslipidemia and increased risk of atherosclerosis associated with the metabolic syndrome.
- Published
- 2008
- Full Text
- View/download PDF
8. Dietary 1,3-diacylglycerol protects against diet-induced obesity and insulin resistance.
- Author
-
Saito S, Hernandez-Ono A, and Ginsberg HN
- Subjects
- Animals, Base Sequence, DNA Primers, Diglycerides administration & dosage, Glucose Tolerance Test, Mice, Polymerase Chain Reaction, Diet, Diglycerides pharmacology, Insulin Resistance, Obesity prevention & control
- Abstract
To investigate the effect of dietary 1,3-diacylglycerol (DAG) on the development of insulin resistance (IR) and obesity, brown adipose tissue-deficient mice, a model of high-fat diet-induced IR and obesity, were fed Western-type diets (WTD) containing either DAG oil (n = 8) or standard triacylglycerol (TAG) oil (n = 9) for 15 weeks, beginning at 8 weeks of age. Although brown adipose tissue-deficient mice became obese on both TAG- and DAG-enriched WTD (TAG-WTD and DAG-WTD), the mice eating DAG-WTD gained less weight and had less body fat accumulation. The results of glucose tolerance tests conducted after 5 weeks of each WTD were not different. However, after 10 weeks of each WTD, impaired glucose tolerance developed in the TAG-WTD group but was prevented by DAG-WTD. Exploratory analyses of gene expression suggested that consumption of DAG-WTD was associated with reduced phosphoenolpyruvate carboxykinase gene expression in liver and increased expression of the genes for peroxisome proliferator-activated receptor alpha, lipoprotein lipase, and uncoupling proteins 2 and 3 in skeletal muscle. There were no effects of the DAG-WTD on fasting and postprandial plasma triglyceride (TG) levels, hepatic TG content, or the rate of secretion of TG from the liver. These findings suggest that diets enriched in 1,3-DAG oil may reduce WTD-induced IR and body fat accumulation by suppressing gluconeogenesis in liver and stimulating fat oxidation in skeletal muscle.
- Published
- 2007
- Full Text
- View/download PDF
9. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis.
- Author
-
Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, and Ginsberg HN
- Subjects
- Adipose Tissue, Brown metabolism, Animals, Apolipoproteins B genetics, Base Sequence, DNA Primers genetics, Disease Models, Animal, Dyslipidemias genetics, Fatty Liver genetics, Female, Gene Expression, Humans, Insulin Resistance genetics, Lipogenesis genetics, Lipogenesis physiology, Male, Mice, Mice, Congenic, Mice, Inbred C57BL, Mice, Transgenic, Obesity genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Dyslipidemias metabolism, Fatty Liver metabolism, Insulin Resistance physiology, Liver metabolism, Obesity metabolism, PPAR gamma genetics, PPAR gamma metabolism
- Abstract
Insulin-resistant apoB/BATless mice have hypertriglyceridemia because of increased assembly and secretion of very low density apolipoprotein B (apoB) and triglycerides compared with mice expressing only apoB (Siri, P., Candela, N., Ko, C., Zhang, Y., Eusufzai, S., Ginsberg, H. N., and Huang, L. S. (2001) J. Biol. Chem. 276, 46064-46072). Despite increased very low density lipoprotein secretion, apoB/BATless mice have fatty livers. We found that hepatic mRNA levels of key lipogenic enzymes, acetyl-CoA carboxylase, fatty-acid synthase, and stearoyl-CoA desaturase-1 were increased in apoB/BATless mice compared with levels in apoB mice, suggesting increased lipogenesis in apoB/BATless mice. This was confirmed by determining incorporation of tritiated water into fatty acids. Neither the hepatic mRNA of the lipogenic transcription factor, SREBP-1c (sterol-response element-binding protein 1c), nor the nuclear levels of the mature form of SREBP-1 protein were elevated in apoB/BATless mice. By contrast, hepatic levels of peroxisomal proliferator-activated receptor 2 (PPARgamma2) mRNA and protein were specifically increased in apoB/BATless mice, as were hepatic mRNA levels of two targets of PPARgamma, CD36 and aP2. Treatment of apoB/BATless mice for 4 weeks with intraperitoneal injections of a PPARgamma antisense oligonucleotide resulted in dramatic reductions of both PPARgamma1 and PPARgamma2 mRNA, PPARgamma2 protein, and mRNA levels of fatty-acid synthase and acetyl-CoA carboxylase. These changes were associated with decreased hepatic de novo lipogenesis and hepatic triglyceride concentrations. We conclude that hepatic steatosis in apoB/BATless mice is associated with elevated rates of hepatic lipogenesis that are linked directly to increased hepatic expression of PPARgamma2. The mechanism whereby hepatic Ppargamma2 gene expression is increased and how PPARgamma2 stimulates lipogenesis is under investigation.
- Published
- 2006
- Full Text
- View/download PDF
10. Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue.
- Author
-
Chen N, Liu L, Zhang Y, Ginsberg HN, and Yu YH
- Subjects
- Adipose Tissue metabolism, Animals, Base Sequence, DNA Primers, Diet, Glucose Tolerance Test, Humans, Lipolysis, Male, Mice, Mice, Inbred Strains, Mice, Transgenic, Obesity, Phosphorylation, Promoter Regions, Genetic, Proto-Oncogene Proteins c-akt metabolism, Receptor, Insulin metabolism, Diacylglycerol O-Acyltransferase genetics, Insulin Resistance genetics
- Abstract
Insulin resistance is often associated with obesity. We tested whether augmentation of triglyceride synthesis in adipose tissue by transgenic overexpression of the diacylglycerol aclytransferase-1 (Dgat1) gene causes obesity and/or alters insulin sensitivity. Male FVB mice expressing the aP2-Dgat1 had threefold more Dgat1 mRNA and twofold greater DGAT activity levels in adipose tissue. After 30 weeks of age, these mice had hyperglycemia, hyperinsulinemia, and glucose intolerance on a high-fat diet but were not more obese than wild-type littermates. Compared with control littermates, Dgat1 transgenic mice were both insulin and leptin resistant and had markedly elevated plasma free fatty acid levels. Adipocytes from Dgat1 transgenic mice displayed increased basal and isoproterenol-stimulated lipolysis rates and decreased gene expression for fatty acid uptake. Muscle triglyceride content was unaffected, but liver mass and triglyceride content were increased by 20 and 300%, respectively. Hepatic insulin signaling was suppressed, as evidenced by decreased phosphorylation of insulin receptor-beta (Tyr(1,131)/Tyr(1,146)) and protein kinase B (Ser473). Gene expression data suggest that the gluconeogenic enzymes, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, were upregulated. Thus, adipose overexpression of Dgat1 gene in FVB mice leads to diet-inducible insulin resistance, which is secondary to redistribution of fat from adipose tissue to the liver in the absence of obesity.
- Published
- 2005
- Full Text
- View/download PDF
11. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue.
- Author
-
Yu YH and Ginsberg HN
- Subjects
- Adiponectin, Animals, Apolipoproteins metabolism, Fatty Acids metabolism, Homeostasis, Hormones, Ectopic physiology, Humans, Insulin metabolism, Insulin Secretion, Intercellular Signaling Peptides and Proteins physiology, Interleukin-6 pharmacology, Islets of Langerhans metabolism, Leptin physiology, Lipoproteins, VLDL metabolism, Liver metabolism, Resistin, Tumor Necrosis Factor-alpha pharmacology, Adipocytes metabolism, Adipose Tissue metabolism, Insulin Resistance, Lipid Metabolism
- Abstract
For many years adipose tissue was viewed as the site where excess energy was stored, in the form of triglycerides (TGs), and where that energy, when needed elsewhere in the body, was released in the form of fatty acids (FAs). Recently, it has become clear that when the regulation of the storage and release of energy by adipose tissue is impaired, plasma FA levels become elevated and excessive metabolism of FA, including storage of TGs, occurs in nonadipose tissues. Most recently, work by several laboratories has made it clear that in addition to FA, adipose tissue communicates with the rest of the body by synthesizing and releasing a host of secreted molecules, collectively designated as adipokines. Several recent reviews have described how these molecules, along with FA, significantly effect total body glucose metabolism and insulin sensitivity. Relatively little attention has been paid to the effects of adipokines on lipid metabolism. In this review, we will describe, in detail, the effects of molecules secreted by adipose tissue, including FA, leptin, adiponectin, resistin, TNF-alpha, IL-6, and apolipoproteins, on lipid homeostasis in several nonadipose tissues, including liver, skeletal muscle, and pancreatic beta cells.
- Published
- 2005
- Full Text
- View/download PDF
12. Regulation of plasma triglycerides in insulin resistance and diabetes.
- Author
-
Ginsberg HN, Zhang YL, and Hernandez-Ono A
- Subjects
- Adipose Tissue metabolism, Animals, Apolipoprotein A-I metabolism, Apolipoproteins B metabolism, Cholesterol metabolism, Chylomicrons metabolism, Fatty Acids metabolism, Humans, Lipid Metabolism, Lipoproteins metabolism, Lipoproteins, HDL metabolism, Lipoproteins, VLDL chemistry, Liver metabolism, Models, Biological, Diabetes Mellitus, Type 2 blood, Insulin Resistance, Triglycerides blood
- Abstract
Increased plasma levels of triglycerides (TG) in very low density lipoproteins (VLDL) are not only common characteristics of the dyslipidemia associated with insulin resistance and type 2 diabetes mellitus (T2DM) but are the central pathophysiologic feature of the abnormal lipid profile. Overproduction of VLDL leads to increased plasma levels of TG which, via an exchange process mediated by cholesterol ester transfer protein (CETP), results in low levels of high density lipoprotein (HDL) cholesterol and apolipoprotein A-I, and the generation of small, dense, cholesterol ester depleted low density lipoproteins (LDL). Increased assembly and secretion of VLDL by the liver results from the complex, post-transcriptional regulation of apolipoprotein B (apoB) metabolism in the liver. In the presence of low levels of hepatic TG and cholesterol, much of the constitutively synthesized apoB is degraded by both proteasomal and non-proteasomal pathways. When excess TG, and to a lesser extent, cholesterol, are present, and in the presence of active microsomal triglycerides transfer protein, apoB is targeted for secretion. The major sources of TG in the liver: uptake of fatty acids (FA) released by lipolysis of adipose tissue TG, uptake of TGFA in VLDL and chylomicrons remnants, and hepatic de novo lipogenesis (the synthesis of FA from glucose) are all abnormally increased in insulin resistance. Treatment of the dyslipidemia in insulin resistant individuals and patients with T2DM has been successful in reducing cardiovascular disease; LDL cholesterol, TG, and HDL cholesterol are all appropriate targets for therapy when diet, exercise, and weight loss do not achieve goals.
- Published
- 2005
- Full Text
- View/download PDF
13. Ovariectomy leads to increased insulin resistance in human apolipoprotein B transgenic mice lacking brown adipose tissue.
- Author
-
Siri PW and Ginsberg HN
- Subjects
- Animals, Blood Glucose analysis, Drug Implants, Estradiol blood, Estrogens administration & dosage, Female, Glucose Tolerance Test, Humans, Hyperlipidemias complications, Insulin blood, Mice, Mice, Inbred Strains, Mice, Transgenic, Obesity complications, Obesity pathology, Obesity physiopathology, Adipose Tissue, Brown pathology, Apolipoproteins B metabolism, Insulin Resistance, Ovariectomy
- Abstract
We studied the role of estrogen in the gender differences in insulin resistance observed in the apoB/BATless mouse, a model of obesity, insulin resistance, and hyperlipidemia. Ovariectomized apoB/BATless mice were more obese and more insulin-resistant than sham ovariectomized apoB/BATless mice. Estrogen replacement by subcutaneous pellet reversed the obesity, lowered plasma insulin levels, and normalized both glucose tolerance and insulin sensitivity associated with ovariectomy. The apoB/BATless mouse should be a good model to delineate the molecular mechanisms whereby estrogen protects against insulin resistance.
- Published
- 2003
- Full Text
- View/download PDF
14. Risk factors common to insulin resistance and atherosclerosis explain why diabetes is a cardiovascular disease.
- Author
-
Ginsberg HN
- Subjects
- Arteriosclerosis epidemiology, Humans, Risk Factors, United States epidemiology, Arteriosclerosis complications, Diabetes Complications, Insulin Resistance
- Published
- 2002
15. Dyslipidemia of insulin resistance syndrome explained; need for treatment to reduce risk emphasized.
- Author
-
Ginsberg HN
- Subjects
- Cholesterol, HDL blood, Cholesterol, LDL blood, Diabetes Complications, Humans, Hyperlipidemias blood, Hyperlipidemias therapy, United States, Hyperlipidemias drug therapy, Insulin Resistance
- Published
- 2002
16. Troglitazone (TGZ) Reduces Plasma apoB and Cholesterol in a Mouse Model with Insulin Resistance and Dyslipidemia
- Author
-
KO, CAROL, SIRI, PATTY, O'ROURKE, SHAWN M., LEE, TSAI-LING, GINSBERG, HENRY N., and HUANG, LI-SHIN
- Subjects
Troglitazone -- Physiological aspects ,Insulin resistance ,Diabetes -- Research ,Health - Abstract
Type 2 diabetes is often associated with insuin resistance, obesity and dyslipidemia. We have previously shown that in the context of brown adipose tissue deficiency, male human apo B transgenic [...]
- Published
- 2000
17. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability.
- Author
-
Pajvani, Utpal B, Qiang, Li, Kangsamaksin, Thaned, Kitajewski, Jan, Ginsberg, Henry N, and Accili, Domenico
- Subjects
RAPAMYCIN ,LIPID synthesis ,INSULIN resistance ,GLUCOSE ,STEROLS ,FATTY liver ,LABORATORY mice - Abstract
Increased hepatic lipid content is an early correlate of insulin resistance and can be caused by nutrient-induced activation of mammalian target of rapamycin (mTor). This activation of mTor increases basal Akt activity, leading to a self-perpetuating lipogenic cycle. We have previously shown that the developmental Notch pathway has metabolic functions in adult mouse liver. Acute or chronic inhibition of Notch dampens hepatic glucose production and increases Akt activity and may therefore be predicted to increase hepatic lipid content. Here we now show that constitutive liver-specific ablation of Notch signaling, or its acute inhibition with a decoy Notch1 receptor, prevents hepatosteatosis by blocking mTor complex 1 (mTorc1) activity. Conversely, Notch gain of function causes fatty liver through constitutive activation of mTorc1, an effect that is reversible by treatment with rapamycin. We demonstrate that Notch signaling increases mTorc1 complex stability, augmenting mTorc1 function and sterol regulatory element binding transcription factor 1c (Srebp1c)-mediated lipogenesis. These data identify Notch as a therapeutically actionable branch point of metabolic signaling at which Akt activation in the liver can be uncoupled from hepatosteatosis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices.
- Author
-
Uriel, Nir, Naka, Yoshifumi, Colombo, Paolo C., Farr, MaryJane, Pak, Sang-Woo, Cotarlan, Vlad, Albu, Jeanine B., Gallagher, Dympna, Mancini, Donna, Ginsberg, Henry N., and Jorde, Ulrich P.
- Subjects
CONGESTIVE heart failure ,MEDICAL equipment ,TREATMENT of diabetes ,INSULIN resistance ,CARDIAC output ,AGE factors in disease ,HYPOGLYCEMIC agents ,PATIENTS - Abstract
Aims Left ventricular assist devices (LVADs) are increasingly used as therapeutic options for patients with advanced congestive heart failure (CHF), many of whom suffer from diabetes mellitus (DM). The aim of this study was to evaluate the effect of restoration of normal cardiac output using LVAD support on diabetes control in patients with advanced CHF. Methods and results A retrospective chart review of all clinic patients supported with long-term LVADs between July 2008 and July 2009 at Columbia University Medical Center was performed. Patients with DM diagnosed prior to device implantation were included in this analysis. Clinical and laboratory data within 1 month preceding and 6 months following LVAD implantation were collected. Of 43 LVAD patients followed in our clinic during the study period, 15 had a diagnosis of DM. Thirteen of the 15 patients were male, mean age was 63 ± 11 years, and the pre-LVAD left ventricular ejection fraction (LVEF) was 16.5 ± 5.7%. Fasting glucose levels, HbA1c, and daily insulin requirement within 1 month before and an average of 4.0 ± 2.3 months after LVAD placement were 157.7 ± 50.6 vs. 104.1 ± 21.4 mg/dL, 7.7 ± 0.9 vs. 6.0 ± 0.8.%, and 53.3 ± 51.7 vs. 24.2 ± 27.2 IU, respectively (P < 0.05 for all comparisons). Six of the 15 patients were completely free of antidiabetic medications and had blood glucose <126 mg/dL as well as HbA1c <6% after LVAD. Body mass index (BMI) was slightly increased after LVAD (28.7 ± 5.3 vs. 30.2 ± 4.1 kg/m2, P NS). Conclusion Restoration of normal cardiac output after LVAD implantation improves diabetic control in patients with advanced CHF. Additional studies are warranted to determine the mechanisms that worsen or possibly induce DM in patients with advanced CHF. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
- Author
-
Thomas-Geevarghese, Asha, Raghavan, Subhashree, Minolfo, Robert, Holleran, Steve, Ramakrishnan, Rajasekhar, Ormsby, Bernard, Karmally, Wahida, Ginsberg, Henry N., El-Sadr, Wafaa M., Albu, Jeanine, and Berglund, Lars
- Abstract
Background: Features of the dyslipidemic pattern reported with the use of antiretroviral therapy predict enhanced postprandial lipemia, which is an emerging cardiovascular disease risk factor. Objective: We evaluated the postprandial response to a physiologic, meal-based challenge in HIV-positive subjects without hyperlipid-emia. Design: We measured hourly lipid, lipoprotein, glucose, and insulin concentrations during a 13-h period in 25 nonwhite patients (13 women, 12 men): 13 receiving a protease inhibitor (PI)-based regimen (6 nelfinavir and 7 indinavir) and 12 receiving a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (6 efavirenz and 6 nevirapine). Results: Mean fasting HDL-cholesterol concentrations were lower in HIV patients than in healthy subjects without HIV infection matched for age, sex, and ethnicity (z score: -0.81 ± 0.9; P = 0.0001). Fasting triacylglycerol concentrations were not significantly different between HIV-infected patients and healthy subjects but were higher in PI-treated than in NNRTI-treated patients [median (interquartile range): 144 (110-191) and 89 (62-135) mg/dL; P = 0.007]. Average daylong triacylglycerol concentrations, but not incremental concentrations, were higher in the PI group than in the NNRTI group [205% (185-248%) and 125% (78-191%); P < 0.05]. For all HIV-positive patients, the fractional triacylglycerol increase was lower after breakfast than after lunch (20 ± 18% and 42 ± 40%, respectively; P < 0.04). Insulin concentrations were higher in PI-treated than in NNRTI-treated patients [22.6 (13.1- 29.8) and 11.8 (7.1-19.1) μU/mL; P = 0.01] and increased in both groups in response to each meal, whereas glucose concentrations increased only after breakfast. Conclusions: Despite baseline differences, incremental triacylglycerol and insulin responses to a physiologic caloric load among HIV-positive patients were not significantly affected by differences in the type of antiretroviral therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
20. The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism.
- Author
-
Yi-Hao Yu and Ginsberg, Henry N.
- Subjects
ACYLTRANSFERASES ,ENZYMES ,LIPIDS ,METABOLISM ,INSULIN ,HOMEOSTASIS ,ADIPOSE tissues ,FATTY acids ,OBESITY - Abstract
Acyl-CoA:diacylglycerol acyltransferase (DGAT, EC2.3.1.20), a key enzyme in triglyceride (TG) biosynthesis, not only participates in lipid metabolism but also influences metabolic pathways of other fuel molecules. Changes in the expression and/or activity levels of DGA1` may lead to changes in systemic insulin sensitivity and energy homeo- stasis. 1-he synthetic role of DGA1- in adipose tissue, the liver, and the intestine, sites where endogenous levels of DGAT activity and TG synthesis are high, is relatively clear. Less clear is whether DGAT plays a mediating or preventive role in the development of ectopic lipotoxicity in tissues such as muscle and the pancreas, when their supply of free fatty acids (FFAs) exceeds their needs. Future studies with tissue- specific overexpression and/or knockout in these animal models would be expected to shed additional light on these issues. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
21. Treatment for patients with the metabolic syndrome
- Author
-
Ginsberg, Henry N.
- Subjects
- *
METABOLIC syndrome , *INSULIN resistance , *DISEASE risk factors , *CARDIOVASCULAR diseases , *MORTALITY , *PEOPLE with diabetes - Abstract
The metabolic syndrome, or insulin resistance syndrome, is associated with increased risk for cardiovascular disease and related mortality and has an estimated age-adjusted US prevalence of 23.7%. Dyslipidemia in the syndrome is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol, and small, dense low-density lipoprotein (LDL) particles in the context of normal/slightly elevated LDL cholesterol. Outcomes in treatment studies in or including diabetic patients suggest that a variety of therapies may be of benefit in reducing cardiovascular risk in patients with the metabolic syndrome, including physiologic therapies and pharmacologic treatments, such as aspirin, antihypertensive therapy, anti-ischemic therapy, and lipid-modifying therapies. The recently updated National Cholesterol Education Program Adult Treatment Panel III guidelines identify the metabolic syndrome as a secondary target of lipid-lowering therapy after LDL cholesterol reduction and recommend use of weight reduction and increased physical activity to address underlying risk factors as well as therapies to address specific lipid and nonlipid risk factors. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
22. Introduction and overview.
- Author
-
Ginsberg, Henry N.
- Subjects
- *
INSULIN resistance , *TYPE 2 diabetes , *CORONARY heart disease treatment , *INSULIN shock , *PATHOLOGICAL physiology - Abstract
Discusses the nature of the insulin-resistant state and the potential impact of insulin resistance on coronary artery disease. Pathophysiology of type 2 diabetes; Epidemiology of insulin resistance and hyperinsulinemia; Dyslipidemia of insulin resistance; Insulin resistance and the vasculature; Relation among dyslipidemia, hypertension, atherosclerosis and insulin resistance.
- Published
- 1999
- Full Text
- View/download PDF
23. Dietary Diacylglycerol Prevents Insulin Resistance and Accumulation of Body Fat in a Mouse Model of Metabolic Syndrome.
- Author
-
Saito, Shinichiro, Hernandez-Ono, Antonio, and Ginsberg, Henry N.
- Subjects
DIGLYCERIDES ,INSULIN resistance ,WEIGHT gain ,ADIPOSE tissues ,METABOLIC syndrome ,LABORATORY mice - Abstract
1,3 -Diacylglycerol (DAG) is a naturally occurring oil that is present at concentrations of several percent in vegetable oils. DAG has a long history of use as a human food. Recently, DAG was reported to suppress postprandial (PP) increases in plasma triglycerides (TG) and prevent weight (wt) gain by increasing PP fat oxidation and energy expenditure compared to control triacylglycerol (TAG) oil. Therefore, we compared the effects of a DAG oil containing Western-type diet (WTD) (21.0% fat, 34.1% sucrose, and 0.2% cholesterol (w/w)) to a control TAG oil-WTD (equal energy content) in brown adipose tissue deficient (BATless) mice, a model of diet-induced metabolic syndrome with obesity and insulin-resistance. Mice were fed either the DAG oil-WTD (n=8) or the standard TAG oil-WTD (n=9) from 8 to 23 wks of age. Both body wt gain and accumulation of body fat were significantly lower in the DAG group during the 15-wk study (wt gain from 8 to 23 wks of age: DAG, 56.3±96.3 vs. TAG, 59.4±16.4%, p<0.001. Total white adipose tissue at 23 wks of age: DAG, 17.0±1:8 vs. TAG, 19.5±1.3 g/100g body wt, p<0.01). By the end of the study, DAG diet had reduced fasting plasma glucose and insulin levels, Glucose tolerance tests (GTTs) performed after 5 wks of each diet showed no differences between the groups for area under the curves (AUC) above baseline for either glucose (G) or insulin (Ins). However; after 10 wks of diet, the AUCs for both G and I were lower on DAG-oil WTD (G: DAG, 57.4±14.7 vs. TAG, 73.5±13.7 g/dL/180min, p<0.05; Ins: DAG, 510.0±184.3 vs. TAG, 868.9±274.1 ng/mL/180min, p<0.01). Thus, the DAG oil-WTD prevented the development of insulin resistance typically seen with TAG oil-WTD. PEPCK mRNA level was reduced in liver, and PPAR alpha, UCP-2 and UCP-3 mRNA levels were increased in skeletal muscle in the DAG oil-WTD group. Additionally, TNF alpha mRNA levels were down-regulated in white adipose tissue. There was no effect of DAG oil-WTD diet on plasma fasting or PP TG levels, hepatic TG, or the rates of TG secretion from the liver. In summary, a WTD containing 1,3-DAG led to less accumulation of body fat and protection from WTD-induced insulin resistance in a mouse model of the metabolic syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2007
24. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents.
- Author
-
Ota, Tsuguhito, Gayet, Constance, and Ginsberg, Henry N.
- Subjects
- *
INSULIN resistance , *FATTY degeneration , *COMPLEMENT inhibition , *LOW density lipoproteins , *HEPATIC encephalopathy , *ENDOPLASMIC reticulum , *ANIMAL experimentation , *APOLIPOPROTEINS , *CELL lines , *COMPARATIVE studies , *CYTOPLASM , *FATTY acids , *FATTY liver , *LIPOPROTEINS , *LIVER , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PROTEOLYTIC enzymes , *RESEARCH , *PHYSIOLOGICAL stress , *TIME , *TRIGLYCERIDES , *UNSATURATED fatty acids , *EVALUATION research - Abstract
ER stress can cause hepatic insulin resistance and steatosis. Increased VLDL secretion could protect the liver from ER stress-induced steatosis, but the effect of lipid-induced ER stress on the secretion of VLDL is unknown. To determine the effect of lipids on hepatic ER stress and VLDL secretion, we treated McA-RH7777 liver cells with free fatty acids. Prolonged exposure increased cell triglycerides, induced steatosis, and increased ER stress. Effects on apoB100 secretion, which is required for VLDL assembly, were parabolic, with moderate free fatty acid exposure increasing apoB100 secretion, while greater lipid loading inhibited apoB100 secretion. This decreased secretion at higher lipid levels was due to increased protein degradation through both proteasomal and nonproteasomal pathways and was dependent on the induction of ER stress. These findings were supported in vivo, where intravenous infusion of oleic acid (OA) in mice increased ER stress in a duration-dependent manner. apoB secretion was again parabolic, stimulated by moderate, but not prolonged, OA infusion. Inhibition of ER stress was able to restore OA-stimulated apoB secretion after prolonged OA infusion. These results suggest that excessive ER stress in response to increased hepatic lipids may decrease the ability of the liver to secrete triglycerides by limiting apoB secretion, potentially worsening steatosis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
25. FoxO transcription factors are required for hepatic HDL cholesterol clearance.
- Author
-
Lee, Samuel X., Heine, Markus, Schlein, Christian, Ramakrishnan, Rajasekhar, Jing Liu, Belnavis, Gabriella, Haimi, Ido, Fischer, Alexander W., Ginsberg, Henry N., Heeren, Joerg, Rinninger, Franz, Haeusler, Rebecca A., and Liu, Jing
- Subjects
- *
INSULIN resistance , *TYPE 2 diabetes , *HIGH density lipoproteins , *TRANSCRIPTION factors , *BLOOD sugar , *CHOLESTEROL - Abstract
Insulin resistance and type 2 diabetes are associated with low levels of high-density lipoprotein cholesterol (HDL-C). The insulin-repressible FoxO transcription factors are potential mediators of the effect of insulin on HDL-C. FoxOs mediate a substantial portion of insulin-regulated transcription, and poor FoxO repression is thought to contribute to the excessive glucose production in diabetes. In this work, we show that mice with liver-specific triple FoxO knockout (L-FoxO1,3,4), which are known to have reduced hepatic glucose production, also have increased HDL-C. This was associated with decreased expression of the HDL-C clearance factors scavenger receptor class B type I (SR-BI) and hepatic lipase and defective selective uptake of HDL cholesteryl ester by the liver. The phenotype could be rescued by re-expression of SR-BI. These findings demonstrate that hepatic FoxOs are required for cholesterol homeostasis and HDL-mediated reverse cholesterol transport to the liver. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.